BIIB and STOK Related Headlines
Go Back- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
- Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
- Stoke Therapeutics names Thomas McCauley as chief scientific officer
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- Stoke Therapeutics completes enrollment in Phase 3 Dravet study
- Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
- Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
- Stoke Therapeutics adds Clare Kahn to board of directors
- Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
- The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
- Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
- Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
- Stoke Therapeutics accelerates Phase 3 trial timeline for Dravet drug
- Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
- Stoke Therapeutics and Biogen present zorevunersen data at epilepsy meeting
- Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 America
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American
- Stoke and Biogen to present zorevunersen data at epilepsy conference
- Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
- Stoke and Biogen publish data showing Dravet syndrome severity
- Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral
- Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral
- Biogen and Stoke present 3-year zorevunersen data for Dravet syndrome
- Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
- Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
- Biogen and Stoke present three-year zorevunersen data for Dravet syndrome
- Stoke Therapeutics and Biogen present 3-year zorevunersen data for Dravet
- Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
- Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
BIIB and STOK Related Press Releases
Go Back- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
- Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
- Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
- Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
- The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
- Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
- Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
- Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
- Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 America
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American
- Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
- Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral
- Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral
- Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
- Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
- Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
- Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
